Asia Pacific Nucleic Acid Therapeutics CDMO Market to Grow with a CAGR of 13.54% through 2028
Surge in research and development activities is expected to drive the Asia
Pacific Nucleic Acid Therapeutics CDMO Market growth in the forecast period,
2024-2028.
According to TechSci Research report, “Asia Pacific
Nucleic Acid Therapeutics CDMO Market – By Country, Competition, Forecast and
Opportunities, 2018-2028F”, the Asia Pacific Nucleic Acid Therapeutics CDMO
Market stood at USD966.15 million in 2022 and is anticipated to grow with a
CAGR of 13.54% in the forecast period, 2023-2028. The initiatives taken by
government based on nucleic acid therapeutics CDMO has led to favorable market
conditions for the Asia Pacific Nucleic Acid Therapeutics CDMO Market. Several
factors contribute to the growth of various nucleic acid therapeutics CDMO market
products.
Policy support
is one of the critical areas where Asia Pacific governments have taken
proactive initiatives. Recognizing the immense potential of the
biopharmaceutical industry, they have developed and implemented favorable
policies that provide a wide range of benefits. These include tax incentives,
subsidies, and grants, aimed at fostering the growth and innovation of the industry.
Notably, these policies extend to the emerging field of nucleic acid
therapeutics Contract Development and Manufacturing Organizations (CDMOs),
further encouraging their establishment and development within the region.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on "Asia Pacific Nucleic Acid Therapeutics CDMO Market”
In recent years,
there has been a significant surge in research and development (R&D)
activities focused on nucleic acid therapeutics. This surge has not only
brought about exciting breakthroughs but has also led to the discovery of new
applications for nucleic acid therapeutics in treating a wide range of
diseases. These diseases include various types of cancer and genetic disorders,
among others.
As a result of
these advancements, the demand for specialized services offered by nucleic acid
therapeutics contract development and manufacturing organizations (CDMOs) has
skyrocketed. These CDMOs play a crucial role in facilitating the development,
scale-up, and manufacturing of nucleic acid therapeutics, thus driving the
overall market growth.
The Asia Pacific
Nucleic Acid Therapeutics CDMO Market is segmented into product type,
technology, regional distribution, and company.
Based on its product type, the custom nucleic acid segment
held the largest share in the market. Nucleic acid therapeutics, with their
ability to target specific genes or genetic sequences associated with chronic
and genetic diseases, offer exciting new possibilities for treatment. These
custom-designed nucleic acids provide a novel approach to tackling these
conditions, potentially revolutionizing the field of medicine. This immense
potential has sparked a surge of interest and investment in the development and
application of custom nucleic acid therapeutics, heralding a new era in
healthcare innovation.
Based on country, China segment is expected to grow
during the forecast period.
One of the key factors that contributes to China's
dominance in the nucleic acid therapeutics CDMO market is its large and highly
skilled workforce. The country's strong emphasis on education, especially in
the sciences, has led to the development of a robust talent pool that actively
supports the biopharmaceutical industry. This well-trained workforce enables
China to effectively meet the demands of the market and maintain its
competitive edge.
In addition to its skilled workforce, the Chinese
government has implemented a range of favorable policies aimed at promoting the
growth of the biopharmaceutical industry. These policies include generous
subsidies and tax incentives, which have not only attracted significant
domestic investment but also encouraged foreign companies to invest in China's
thriving biopharmaceutical sector. The combination of these policies and
investments has created a favorable environment for the industry to flourish,
driving innovation and further strengthening China's position in the market.
Major companies operating in Asia Pacific Nucleic Acid
Therapeutics CDMO Market are:
- Asymchem Inc.
- BioCina Pty Ltd.
- CMIC HOLDINGS Co., Ltd.
- Kaneka Corporation
- Nippon Shkubai Co., Ltd
- Nitto Inc.
- ST Pharm Co Ltd
Download Free Sample Report
Customers can also request for 10%
free customization on this report
“Growing application of nucleic acid therapeutics CDMO
in various end user industries are key drivers of the nucleic acid therapeutics
CDMO market. Growth in competitive landscape and presence of well-established
companies in the market who are dedicated to enhance their productivity of nucleic
acid therapeutics CDMO with every passing year are anticipated to register an
impressive growth to Asia Pacific Nucleic Acid Therapeutics CDMO Market in the
forecast period.,” said Mr. Karan Chechi, Research Director with TechSci
Research, a research-based management consulting firm.
“Asia Pacific Nucleic Acid Therapeutics CDMO Market By Product
Type (Standard Nucleic Acid, Micro-Scale Nucleic Acid, Large-Scale Nucleic
Acid, Custom Nucleic Acid, Modified Nucleic Acid, Primers, Probes, Others), By Technology
(Column-Based Method, Microarray-Based Method), By
Country, By Competition Forecast & Opportunities, 2018-2028F”, has evaluated
the future growth potential of Asia Pacific Nucleic Acid Therapeutics CDMO
Market and provides statistics & information on market size, structure, and
future market growth. The report intends to provide cutting-edge market
intelligence and help decision makers take sound investment decisions. Besides,
the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in Asia Pacific Nucleic Acid
Therapeutics CDMO Market.
Contact
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com